CADTH CDEC final recommendation: Empagliflozin (Jardiance -- Boehringer Ingelheim (Canada) Ltd.) indication : Type 2 Diabetes mellitus
The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin be listed for the treatment of type 2 diabetes
Corporate Authors: | , |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
October 15, 2015, 2015
|
Series: | CADTH common drug review
|
Subjects: | |
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The CADTH Canadian Drug Expert Committee (CDEC) recommends that empagliflozin be listed for the treatment of type 2 diabetes |
---|---|
Physical Description: | 1 PDF file (6 pages) |